RCE to present at the 2023 American College of Cardiology - Late Breaking Clinical Trials

Carlsbad, California (December 20, 2022) - RCE Technologies, Inc. has been accepted to present at the American College of Cardiology - Late Breaking Clinical Trials. The presentation titled, "A Novel Breakthrough In Wrist-Worn Transdermal Troponin-I-Sensor Assessment For Acute Myocardial Infarction" will be delivered center stage on March 6, in New Orleans, Louisiana, by Dr. Partho Sengupta, Henry Rutgers Professor of Cardiology and Division Chief of Cardiology at the Rutgers Robert Wood Johnson Medical Center.

The selection process was highly competitive. Presenting our research at the Annual Scientific Session represents a critical contribution to the evolving science and innovative strategies that are central to the experience at ACC.23/WCC.

In Founder & CEO, Atandra Burman’s own words, "Dr. Sengupta will be presenting novel insights from our recent multi-site study, to a live audience of a few hundred clinicians, health care executives and strategic investors in person, with live broadcast worldwide. While the abstract cannot be shared publicly, we anticipate this bringing high visibility to RCE's scientific validation efforts. We very much appreciate the team’s exceptional effort on the clinical execution and data analysis fronts. This would especially not be possible without the trust and support imparted in RCE by our investors and the timely deployment of capital to keep us on track."

About RCE:

RCE.ai, an innovative artificial intelligence (AI) based medical technology company launched in Carlsbad, Calif., in 2018, is dedicated to early heart attack detection. The company has revolutionized the monitoring of cardiac injury by introducing Infrasensor™, a non-invasive infrared-based wearable device. RCE’s proprietary transdermal approach, enhanced with deep learning techniques, analyzes and associates unique optical signatures with cardiac conditions in real-time. This AI-coupled transdermal approach enables the potential application of RCE’s technology in various emergency care settings and remote monitoring applications. Presently, RCE is engaged in clinical studies to optimize the Infrasensor for clinical use. Through ongoing clinical studies, the company hopes to soon secure FDA approval for its technology, opening the door to making it available for sale in the United States. 

For more information, please visit https://rce.ai/contact, follow us on LinkedIn or X (formerly Twitter), or contact RCE Investor Relations at ir@rce.ai